There are currently 1025 ongoing clinical trials involving Skin Cancer
Of the 1025 trials,354 trials are in Phase II
Furthermore, 309 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Skin Cancer, an oncology condition. The largest number of ongoing clinical trials for Skin Cancer is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Skin Cancer-related drug trials.
University of Texas MD Anderson Cancer Center: The leading ongoing Skin Cancer related clinical trial sponsor
University of Texas MD Anderson Cancer Center is the top sponsor for Skin Cancer-related ongoing clinical trials.
National Cancer Institute US, Bristol-Myers Squibb Co, Merck & Co Inc, H. Lee Moffitt Cancer Center & Research Institute Inc, and Novartis AG are among other notable clinical trial sponsors involved in Skin Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Skin Cancer
Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Atezolizumab (Tecentriq) are key marketed drugs involving Skin Cancer.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Keytruda is formulated as lyophilized powder for solution, solution concentrate for intravenous route of administration. Keytruda is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation-positive, a BRAF inhibitor. Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Pembrolizumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Merck Sharp & Dohme Corp.
Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 Antagonist mechanism of action. Opdivo is formulated as a solution and concentrate solution for intravenous route of administration. Nivolumab is indicated for the treatment of unresectable melanoma. Opdivo as a single agent is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation was positive, a BRAF inhibitor. Nivolumab was first approved in 2014 and is marketed globally including in the US, the UK, Australia, France, Germany, China, and Japan by Bristol-Myers Squibb Co.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward